Skip to content
Clinical Trials – home

Alogabat: A Potential Treatment for Angelman Syndrome in Children and Adolescents

0 / 1
trials open to patients / all trials
1+
Countries

In short

This article explores a clinical trial investigating the use of alogabat in children and adolescents aged 5-17 years with Angelman Syndrome (AS). The study aims to examine the drug's pharmacokinetics, safety, and effectiveness in this specific population. The trial is designed to provide valuable insights into how alogabat may benefit individuals with AS, particularly those with the deletion genotype.

At a glance

Study Type
Phase IIa, multicenter, open-label, 12-week study
Participants
Up to 56 children and adolescents aged 5-17 years with Angelman Syndrome (deletion genotype)
Drug
Alogabat, administered once daily (QD)
Study Structure
Two parts: Part 1 (dose confirmation) and Part 2 (dose exploration)
Primary Outcomes
Plasma pharmacokinetics, EEG beta-band power changes
Secondary Outcomes
Safety assessments, treatment discontinuations, daytime sleepiness
Age Groups
5-9 years, 10-14 years, 15-17 years

What is alogabat?

Alogabat is a new medication currently being studied for its potential use in treating Angelman Syndrome in children and adolescents. It's important to note that alogabat is still in the research phase and is not yet approved for general use. The ongoing study aims to understand how the drug works in young patients and to determine its safety profile.

What condition does alogabat target?

Alogabat is being investigated specifically for Angelman Syndrome (AS) with deletion genotype. Angelman Syndrome is a rare genetic disorder that affects the nervous system and causes developmental problems, including delayed development, intellectual disability, severe speech impairment, and problems with movement and balance. The "deletion genotype" refers to a specific genetic cause of AS, where a portion of a chromosome is missing.

How is the study designed?

The study of alogabat is designed as a Phase IIa, multicenter, open-label, 12-week study. Here's what this means:

  • Phase IIa: This is an early stage of clinical research that aims to assess how well the drug works and to further evaluate its safety.
  • Multicenter: The study is being conducted at multiple hospitals or research centers.
  • Open-label: Both the researchers and the participants know which treatment is being given.
  • 12-week study: The study will last for 12 weeks for each participant.

The study is divided into two parts:

  1. Part 1 - Dose confirmation: This part will help determine the right dose for different age groups.
  2. Part 2 - Extended treatment: This part will explore how the drug affects brain activity over a longer period.

The study will enroll up to 56 participants with Angelman Syndrome, aged 5-17 years.

How is alogabat administered?

Alogabat is given as a daily dose, with the amount adjusted based on the participant's age. The study uses different dosing strategies for different age groups:

  • Ages 15-17: Receive the adult dose of 60 mg per day
  • Ages 10-14: Receive an age-adjusted equivalent of the adult 60 mg dose
  • Ages 5-9: Receive an age-adjusted equivalent of the adult 20 mg dose

In Part 2 of the study, the doses may be adjusted based on the results from Part 1, with the possibility of using doses equivalent to up to 100 mg in adults.

What are the study outcomes?

The study aims to measure several outcomes to understand how alogabat works in children and adolescents with Angelman Syndrome:

  • Pharmacokinetics: This involves measuring how the drug moves through the body, including how it's absorbed, distributed, and eliminated. The study will compare these measurements in children to those in adults.
  • Brain activity: The study will measure changes in brain activity using electroencephalography (EEG), specifically looking at changes in the "beta band" of brain waves.
  • Safety: The researchers will monitor for any side effects or adverse events throughout the study.

How is safety monitored?

The study includes several measures to monitor the safety of alogabat:

  • Tracking the occurrence and severity of any side effects or serious adverse events
  • Monitoring for any participants who need to stop the treatment due to side effects
  • Assessing daytime sleepiness using a scale called the Karolinska Sleepiness Scale (KSS)
  • Keeping a diary to track any sudden onset of sleep

These safety measures are crucial in determining whether alogabat could be a safe and effective treatment for children and adolescents with Angelman Syndrome in the future.

Questions people often ask

Trials with Alogabat

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.